Sodium-glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside

Bahador Bagheri; Habib Yaribeygi; Erfan Taherifard; Azita Hajhossein Talasaz; Haleh Bagheri; Mahboubeh Darban; Reza Tabrizi; Siamak Najafi; Mahmoud Khodadost; Maryam Akbari

doi:10.1111/fcp.12852

Sodium-glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside

Fundam Clin Pharmacol. 2023 Jun;37(3):481-492. doi: 10.1111/fcp.12852. Epub 2022 Dec 27.

Authors

Bahador Bagheri^{1

2}, Habib Yaribeygi³, Erfan Taherifard⁴, Azita Hajhossein Talasaz⁵, Haleh Bagheri⁶, Mahboubeh Darban⁷, Reza Tabrizi^{8

9

10}, Siamak Najafi¹¹, Mahmoud Khodadost¹², Maryam Akbari¹³

Affiliations

¹ Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
² Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
³ Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
⁴ Department of Internal Medicine, Shiraz University of Medical Sciences, Fars, Iran.
⁵ Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, Virginia, USA.
⁶ Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.
⁷ Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran.
⁸ Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
⁹ USERN office, Fasa University of Medical Sciences, Fasa, Iran.
¹⁰ Clinical Research Development Unit, Fasa University of Medical Sciences, Fasa, Iran.
¹¹ Department of Internal Medicine, Fasa University of Medical Sciences, Fasa, Iran.
¹² Department of Public Health, Larestan University of Medical Sciences, Larestan, Iran.
¹³ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 36399066
DOI: 10.1111/fcp.12852

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2is) are oral medications approved for type 2 diabetes mellitus. Interestingly, during recent years, they have been promisingly considered as new medications for cardiovascular and kidney diseases. However, the mechanisms underlying these new benefits are not fully understood. Thanks to the discovery of multiple modes of action, the simple picture about mechanisms of action of SGLT2is has become more and more complex. Besides their effects in diabetes, there is increasing evidence for their beneficial effects in heart failure and chronic kidney diseases. In addition, many studies have provided evidence for the fruitful effects of SGLT2is in atherosclerotic cardiovascular disease. In this study, we present mounting evidence for the complex action modes of SGLT2is and their current applications in clinical practice.

Keywords: Sodium-glucose cotransporter 2 inhibitors; chronic kidney disease; diabetes mellitus; heart failure.

Publication types

Review

MeSH terms

Cardiovascular Diseases* / drug therapy
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucose
Sodium

Abstract

Publication types

MeSH terms

Substances

Grants and funding